0001209191-22-023845.txt : 20220408
0001209191-22-023845.hdr.sgml : 20220408
20220408160949
ACCESSION NUMBER: 0001209191-22-023845
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220406
FILED AS OF DATE: 20220408
DATE AS OF CHANGE: 20220408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoelscher Paul W.
CENTRAL INDEX KEY: 0001611468
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35238
FILM NUMBER: 22817083
MAIL ADDRESS:
STREET 1: 520 LAKE COOK ROAD, SUITE 520
STREET 2: C/O HORIZON PHARMA, INC.
CITY: DEERFIELD
STATE: IL
ZIP: 60062
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co
CENTRAL INDEX KEY: 0001492426
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 011-353-1-772-2100
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: Horizon Pharma plc
DATE OF NAME CHANGE: 20140919
FORMER COMPANY:
FORMER CONFORMED NAME: HORIZON PHARMA, INC.
DATE OF NAME CHANGE: 20100520
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-06
0
0001492426
Horizon Therapeutics Public Ltd Co
HZNP
0001611468
Hoelscher Paul W.
C/O HORIZON THERAPEUTICS PLC,
70 ST. STEPHEN?S GREEN
DUBLIN
L2
D02 E2X4
IRELAND
0
1
0
0
EVP, CFO
Ordinary Shares
2022-04-06
4
M
0
30275
15.96
A
31324
D
Ordinary Shares
2022-04-06
4
M
0
185060
22.14
A
216384
D
Ordinary Shares
2022-04-06
4
S
0
215335
110.009
D
1049
D
Ordinary Shares
2022-04-06
4
S
0
91710
110.0101
D
66673
I
By LLC
Ordinary Shares
72789
I
By Trust
Stock Option (Right to Buy)
15.96
2022-04-06
4
M
0
30275
0.00
D
2024-06-26
Ordinary Shares
30275
0
D
Stock Option (Right to Buy)
22.14
2022-04-06
4
M
0
185060
0.00
D
2025-03-22
Ordinary Shares
185060
86424
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC.
The option is fully vested and exercisable.
/s/ Miles W. McHugh, Attorney-in-Fact
2022-04-08